The institute has a Pharmacovigilance Committee (PvC) chaired by Dean. The PvC conducts regular meetings to discuss various issues regarding the effective implementation of Pharmacovigilance Programme of India (PvPI), Indian Pharmacopoeia Commission (IPC) under Ministry of Health and Family Welfare, Government of India.
|Pharmacovigilance Committee (PvC)|
|I/C Medical Superintendent||Member|
|HOD Pharmacology & Coordinator, ADR Moni. Centre||Member Secretary|
|HOD Obstetrics & Gynaecology||Member|
|HOD Skin & VD||Member|
|HOD Forensic Medicine &Toxicology||Member|
|Dy- Coordinator, ADR Moni.Centre||Member|
|I/C Blood Bank, SMIMER||Member|
The institute has been designated as Adverse Drug Reaction (ADR) Monitoring Centre under Pharmacovigilance Programme of India (PvPI) in December 2012, by Indian Pharmacopoeia Commission (IPC) under Ministry of Health and Family Welfare, Government of India. ADR Monitoring (Pharmacovigilance) Centre (AMC) is located in the Department of Pharmacology and HOD Pharmacology is the Coordinator.
PvPI is concerned with reporting of ADR “to ensure the benefits of use of medicine outweigh the risk and so safeguarding the health of Indian Population” i.e. Safe use of medicines. Apart from ADR monitoring of drugs, Haemovigilance (Adverse Events/ Reactions associated with Blood Transfusion & Blood Products Administration) and Biovigilance Programme (Adverse Events/Reactions during tissue, Organ & Cell Therapy Transplantation) have also been included under PvPI.
Reporting of ADR is voluntary, however, it can be considered as ethical and moral duty of every medical professional to ensure the safety of patients while providing treatment, whether by medicines or by other means. Now, it is very convenient for staff members by sparing just five minutes of their valuable time to report adverse drug reactions (including that arise due to blood and bloods products and tissue transplantation) to AMC of SMIMER. The ADRs reported are sent every month to IPC (www.ipc.gov.in) for necessary action (intervention) and further onward submission to WHO.